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We	conducted	a	 longitudinal	 community	cohort	 study	
of	healthy	adults	 in	 the	UK.	We	 found	significantly	higher	
incidence	of	influenza	A(H1N1)pdm09	infection	in	2010–11	
than	in	2009–10,	a	substantial	proportion	of	subclinical	in-
fection,	and	higher	risk	for	infection	during	2010–11	among	
persons with lower preinfection antibody titers.
Case-based population-level surveillance and cross-sectional serologic surveys to estimate incidence and 
patterns of influenza infection are limited by the lack of ac-
curate denominator data, inability to account for subclini-
cal infections, difficulties in distinguishing between anti-
bodies induced by natural infection and vaccination, and 
use of samples from high-risk groups. For these reasons, 
community-based longitudinal studies are ideal to estimate 
the incidence of infection and spectrum of illness. How-
ever, studies of this design describing the 2009 pandemic 
of influenza A(H1N1)pdm09, reported only from Hong 
Kong, Singapore, and Vietnam, examine only the 2009–10 
season (1–3).
The epidemiology of A(H1N1)pdm09 in the United 
Kingdom during 2009–2011 was characterized by 3 dis-
tinct waves: first wave, April–August 2009; second wave, 
September 2009–April 2010; and third wave, August 
2010–April 2011. We report results from a community-
based longitudinal cohort study that compared the epi-
demiology of influenza A(H1N1)pdm09 infection over 
the second and third waves. The North West London Re-
search Ethics Committee approved this study (reference 
09/H0724/27).
The Study
A total of 342 healthy adult staff and students of Impe-
rial College London (London, UK) were recruited during 
September–November 2009 and followed for 2 consecu-
tive influenza seasons: 2009–10 and 2010–11 (Figure 1). 
Participants’ median age was 28 years (interquartile range 
20–36 years); 83% were <40 years of age. At each time 
point, collected serum samples were tested for antibodies 
to A(H1N1)pdm09 virus (A/England/195/09 strain) by the 
hemagglutination-inhibition (HI) assay (4). Participants 
were asked to record temperature, self-sample, and return 
nasal swabs when experiencing influenza-like symptoms. 
Swabs were tested for respiratory viruses with standardized 
real-time reverse transcription PCR. Influenza seropreva-
lence rates were defined as the proportion of persons with 
HI titers >32 (4).
Because our study began at the end of the first pan-
demic wave, cumulative incidence of A(H1N1)pdm09 in-
fection over the first wave was estimated as the difference 
between age-specific seroprevalence rates at recruitment 
(T0 in Figure 1) and published prepandemic (2008) sero-
prevalence rates for England (4). Incident infection was 
defined as antibody seroconversion (4-fold rise in HI titer) 
in paired serum samples collected at the start and end of a 
wave among unvaccinated persons (because HI assay can-
not differentiate infection from vaccination) or detection 
of A(H1N1)pdm09 virus in nasal swabs. The incidence of 
infection was estimated for the second and third waves as 
the proportion of incident infections among unvaccinated 
participants.
Development of any symptoms was recorded on 
a Web-based questionnaire emailed to participants ev-
ery 3 weeks. The average response rate was 75%. Illness 
episodes were categorized as acute respiratory infection 
(episode with any symptoms), influenza-like illness ([ILI] 
episode with fever plus cough or sore throat), and fever (re-
corded temperature >38°C) alone. Visits to primary care or 
hospital during illness were also recorded. Data were ana-
lyzed using Stata version 9.0 (StataCorp, College Station, 
TX, USA) with the χ2 test to compare proportions and t test 
to compare means after checking for normal distribution by 
assessing for kurtosis, skewness, and the Shapiro-Wilk test. 
Hosmer-Lemeshow test was used to estimate goodness-of-
fit for each logistic regression.
At recruitment, after the first pandemic wave, A(H1N1)
pdm09 seroprevalence was 26% (95% CI 21.4–31.2), with 
seroprevalence significantly higher in participants 18–25 
years of age than in older age groups (Table 1). Participants 
with ILI in the preceding 3 months corresponding to the first 
wave had significantly higher (p<0.001) mean A(H1N1)
pdm09 virus HI titers, which in conjunction with the age 
distribution, suggests first-wave infection rather than 
cross-reactive antibodies (5). Overall cumulative incidence 
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during the first wave was 12.7% (95% CI 7.1%–18.4%) 
and 26.6% (95% CI 15.3%–37.8%) among participants 
18–25 years of age with no increase in older age groups 
(online Technical Appendix Table 1, wwwnc.cdc.gov/EID/
articlepdfs/19/11/13-0295-Techapp1.pdf ).
The incidence of infection over the third pandemic 
wave was significantly higher (p = 0.02) than over the sec-
ond wave (Figure 1). Among participants with prewave ti-
ters <8, the incidence of infection was significantly higher 
over the third wave than over the second wave (p<0.001); 
incidence did not differ for participants with prewave 
titers >8 (Table 2, Appendix, wwwnc.cdc.gov/EID/
article/19/11/13-0293-T2.htm). Age-specific incidence was 
significantly higher (p = 0.01) over the third wave than the 
second wave among participants 26–40 years of age (third 
wave: 25.4% [95% CI 15.2–35.5]; second wave: 10.9% 
[95% CI 5.1–16.7]) but not the other age groups (Table 2, 
Appendix). For 11 infected participants with paired serum 
samples and virus detected in nasal swabs, 2 (18%) did not 
show antibody seroconversion (online Technical Appendix 
Table 2).
During an illness episode, 20% of infected participants 
reported fever or ILI, 17% visited their general practitioner, 
and none visited a hospital (Figure 2). Because predictions 
	 Emerging	Infectious	Diseases	•	www.cdc.gov/eid	•	Vol.	19,	No.	11,	November	2013	 1867
Figure	1.	Incidence	of	natural	influenza	A(H1N1)pdm09	infection	in	the	study	cohort	during	the	3	pandemic	waves	in	context	of	the	evolving	
pandemic,	United	Kingdom.	Study	outline	is	depicted	in	the	upper	panel	in	temporal	context	of	the	pandemic	during	the	2009–2011	influenza	
seasons.	The	bar	chart	shows	UK	influenza	virologic	surveillance	data	from	WHO	Flunet	(www.who.int/influenza/gisrs_laboratory/flunet/
en/)	highlighting	the	periods	of	study	recruitment	and	follow-up	in	relation	to	influenza	A	activity	in	the	United	Kingdom	during	2009–2011.	
Light	gray	bars	indicate	influenza	A	of	all	subtypes;	dark	gray	bars	indicate	the	number	of	A(H1N1)pdm09	cases	detected	by	virologic	
national	surveillance.	Healthy	adults	were	recruited	after	the	first	pandemic	wave	(April–August	2009)	had	ended	in	the	United	Kingdom	
and	were	followed	over	2	influenza	seasons,	with	serum	samples	collected	before	and	at	the	end	of	each	influenza	season.	The	median	
time	between	visits	is	shown.	The	second	wave	was	defined	as	baseline	(September–November	2009)	to	first	follow-up	(February–April	
2010)	and	the	third	wave	as	the	time	between	the	second	follow-up	(August–November	2010)	and	the	third	follow-up	(February–April	
2011).	The	light	gray	bracket	and	numerals	represent	the	estimated	cumulative	incidence	of	infection	over	the	first	pandemic	wave	by	
calculating	the	difference	between	and	seroprevalence	rates	at	baseline	in	the	cohort	and	prepandemic	(2008)	published	seroprevalence	
rates.	Infection	was	defined	as	detection	of	A(H1N1)pdm09	virus	in	nasal	swabs	returned	during	the	second	or	third	wave	or	a	4-fold	rise	
in	A(H1N1)pdm09	virus	HI	titer	in	paired	serum	samples	collected	at	the	start	and	end	of	each	wave.	The	number	of	infected	persons	
with	total	persons	at	risk	during	each	of	the	second	and	third	waves	with	calculated	incidence	rate	and	95%	CIs	are	shown.	WHO,	World	
Health	Organization;	IQR,	interquartile	range;	HI,	hemagglutination-inhibition.	*Infection	rates	in	the	first	wave	reflect	cumulative	incidence	
of	infection,	estimated	by	calculating	the	difference	in	proportion	of	persons	with	HI	titer	>32	between	baseline	(T0)	and	published	Health	
Protection	Agency	data	before	the	pandemic	in	2008.
of a small third pandemic wave were disproved (4), the 
reasons for this large wave remained unclear. Multivari-
ate logistic regression was undertaken with infection as the 
dependent variable and age, sex, and prewave titers as in-
dependent variables. Each doubling increase in prewave HI 
titers, after adjustment for age and sex, was associated with 
significantly lower risk for infection (odds ratio 0.92, 95% 
CI 0.9–1.0, p = 0.04) during the third, but not the second, 
wave (Table 2, Appendix).
Conclusions
Incidence of A(H1N1)pdm09 infection was sig-
nificantly higher among healthy adults during the third 
pandemic wave (2010–11) than during the second wave 
(2009–10). This study complements and corroborates clini-
cal surveillance data and population-sampling seroepide-
miology from the United Kingdom (4,6,7), United States 
(8) and elsewhere (9).
The reasons for this unexpectedly larger third wave 
in the postpandemic season remain unclear. We show an 
increased risk for A(H1N1)pdm09 infection associated 
with lower antibody levels at the start of the season, irre-
spective of age, during the third, but not the second, wave. 
Because no substantial viral genetic change occurred be-
tween the waves (7), our finding suggests that the third 
wave was driven by infection among susceptible persons 
remaining antibody-naive at the end of the second wave. 
This thesis is supported by serosurveillance data showing 
lower infection rates over the third wave among age groups 
with the highest infection rates over previous pandemic 
waves (7,8). Our interpretation is further strengthened by a 
meta-analysis of serologic data from 19 countries that 
showed 20%–27% incidence of infection during the first 
pandemic year, suggestive of a large population susceptible 
to infection in subsequent seasons (10).
Incidence in our cohort was lower than that estimated 
for England by cross-sectional serosurveys (7,11). This 
finding may reflect our accounting for individual-level 
vaccination status and baseline antibody titers; data usu-
ally unobtainable with cross-sectional population-sample 
serosurveys. However, our study did not include children 
or elderly persons, which limits the generalizability of our 
findings. A major advantage of longitudinal cohort studies 
recording clinical data is identification of subclinical and 
asymptomatic infections. More than 80% of participants 
did not seek primary care or have surveillance-defined ILI 
indicating a high proportion of subclinical infection among 
healthy adults undetectable by routine case-based surveil-
lance. We also describe persons shedding virus without 
antibody seroconversion, a phenomenon recently report-
ed in Vietnam and the United Kingdom (4,12). Although 
these nonseroconverters might have antibodies detectable 
by microneutralization assay, such nonseroconverters, 
undetectable by serosurveys using the standard HI assay, 
further highlight the possibility of underestimating com-
munity infection rates when cross-sectional serosurveys 
alone are used. 
Despite our intensive symptom ascertainment, 4 par-
ticipants with influenza reported no symptoms. Cross-re-
active cellular immune responses that are highly prevalent 
in the population (13) have recently been shown to be as-
sociated with protection against symptomatic illness (14). 
Our analysis of pandemic influenza in a commu-
nity cohort over successive seasons offers insight into 
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Table	1.	Seroprevalence	of	influenza	A(H1N1)pdm09	antibodies	at	baseline,	United	Kingdom,	2009–2011* 
 Risk	factor 
HI titer, no. (%)† 
GMT	(95%	CI) p value§ <8 8–32 >32 Total p value‡ 
Total  202	(62.0) 39	(12.0) 85	(26.1) 326  11.6	(10.0–13.4)  
Sex        
 M 92	(58.2) 22	(13.9) 44	(27.8) 158 0.48 12.8	(10.3–15.8) 0.19 
 F 110	(65.5) 17	(10.1) 41	(24.4) 168  10.6	(8.7–12.8)  
Age	group,	y¶        
 18–25 57	(44.9) 15	(11.8) 55	(43.3) 127 Ref 20.4	(15.5–26.8) Ref 
 26–40 99	(73.9) 19	(14.2) 16	(11.9) 134 <0.001 7.8	(6.6–9.1) <0.001 
 41–55 32	(74.4) 2	(4.7) 9	(20.9) 43 0.01 8.6	(6.2–11.8) <0.001 
 >56 9	(64.3) 1	(7.1) 4	(28.6) 14 0.29 9.2	(5.3–16.0) 0.14 
Seasonal	influenza	vaccination	in	2008#       
 Yes 23	(54.8) 5	(11.9) 14	(33.3) 42 0.19 12.6	(8.6–18.3) 0.56 
 No 174	(64.2) 32	(11.8) 65	(24.0) 271  11.1	(9.5–13.0)  
Self-reported	history	of	ILI	in	3	mo	before	recruitment**      
 Yes 9	(36.0) 3	(12.0) 13	(52.0) 25 <0.01 35.7	(16.5–77.0) <0.001 
 No 189	(64.3) 36	(12.2) 69	(23.5) 294  10.5	(9.2–12.1)  
*HI,	hemagglutination	Inhibition;	GMT,	geometric	mean	titer;	Ref,	referent;	ILI,	influenza-like illness. 
†Of the 342 participants in the study, 16 were missing data on HI assay results. 
‡p	value	comparing	the	number	of	persons	with	a	titer	>32. 
§p value	comparing	the	GMT.	For	age	categories,	p	value	represents	the	test	for	trend. 
¶Data	available	for	314	persons. 
#Data	available	for	313	persons. 
**Data	available	for	319	persons. 
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contributors of the unexpectedly larger third pandemic 
wave. Our analysis also highlights the necessity of using 
cohorts to complement routine case-based surveillance 
to estimate influenza burden.
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Figure	2.	Proportion	of	influenza	A(H1N1)pdm09–infected	persons	
who had symptoms during their illness episode during the second 
wave	(September	2009–April	2010),	third	wave	(August	2010–April	
2011),	 and	 entire	 study	 period,	 United	 Kingdom.	 Proportion	 of	
persons with reported symptoms over the study period is combined 
from the second and third waves. Symptoms were recorded by a 
Web-based	symptom	questionnaire	emailed	 to	participants	every	
3	weeks.	 Symptoms	 associated	with	 illness	 episode	were	 acute	
respiratory	 infection	 (ARI;	 illness	 episode	 with	 any	 symptoms),	
influenza-like	 illness	 (ILI;	 episode	 with	 fever	 plus	 cough	 or	 sore	
throat),	 fever	 (recorded	 temperature	 >38°C)	 alone,	 or	 visit	 to	 a	
general	practitioner	(GP).	The	graph	depicts	the	average	with	95%	
CIs	calculated	by	using	binomial	distribution.
